Merus (NASDAQ:MRUS) Research Coverage Started at Wells Fargo & Company

Wells Fargo & Company began coverage on shares of Merus (NASDAQ:MRUS) in a research note published on Friday morning, Marketbeat.com reports. The brokerage issued an overweight rating and a $91.00 price objective on the biotechnology company’s stock.

MRUS has been the topic of a number of other reports. HC Wainwright reaffirmed a “buy” rating and set a $85.00 target price on shares of Merus in a report on Monday, December 2nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $85.00 price objective on shares of Merus in a research note on Monday, December 9th. UBS Group started coverage on shares of Merus in a report on Thursday, October 24th. They issued a “buy” rating and a $72.00 target price on the stock. Guggenheim restated a “buy” rating and set a $109.00 target price (down from $111.00) on shares of Merus in a report on Tuesday, December 3rd. Finally, The Goldman Sachs Group started coverage on Merus in a report on Thursday, November 21st. They issued a “buy” rating and a $73.00 price target on the stock. One investment analyst has rated the stock with a sell rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $86.08.

Merus Stock Down 0.7 %

MRUS stock opened at $41.25 on Friday. The company has a 50-day simple moving average of $42.10 and a 200 day simple moving average of $47.61. The company has a market capitalization of $2.82 billion, a P/E ratio of -10.44 and a beta of 1.11. Merus has a fifty-two week low of $37.66 and a fifty-two week high of $61.61.

Institutional Trading of Merus

Several hedge funds and other institutional investors have recently modified their holdings of MRUS. HighTower Advisors LLC boosted its position in Merus by 10.9% during the 4th quarter. HighTower Advisors LLC now owns 8,020 shares of the biotechnology company’s stock worth $337,000 after acquiring an additional 789 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Merus in the fourth quarter worth $347,000. Arizona State Retirement System boosted its holdings in Merus by 9.6% during the fourth quarter. Arizona State Retirement System now owns 13,833 shares of the biotechnology company’s stock worth $582,000 after purchasing an additional 1,209 shares during the last quarter. Impax Asset Management Group plc bought a new position in Merus in the fourth quarter valued at $7,569,000. Finally, HealthInvest Partners AB increased its stake in Merus by 23.3% in the 4th quarter. HealthInvest Partners AB now owns 62,521 shares of the biotechnology company’s stock valued at $2,619,000 after buying an additional 11,834 shares during the last quarter. Institutional investors and hedge funds own 96.14% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.